微小残留病灶在多发性骨髓瘤中的临床意义及其检测方法

摘要

多发性骨髓瘤(multiple myeloma,MM)患者的治疗效果在过去十年中逐步提升,具体表现为无进展生存期及总生存期的延长,许多患者经治疗后可达到完全缓解.同时,大多数研究表明,微小残留病灶(minimal residualdisease,MRD)的相关信息可代替总生存率评估不同治疗方案的有效性.近年来,多参数流式细胞术、聚合酶链式反应、二代测序技术及PET/CT等检测MM患者MRD的高敏感试验也在逐步开展.本文仅就MRD的临床意义及上述4种检测方法各自的特征作一综述.%The outcomes for the patients with multiple myeloma (MM) have been improved substantially in both progression-free survival and overall survival in the past decade.Many patients are now achieving a complete response to treatments.Extensive data indicate that the information about minimal residual disease (MRD) can be used potentially as a biomarker to evaluate the efficacy of different treatment strategies instead of overall survival.Consequently,highly sensitive assays have been already used in progress for detection of MRD in the patients with MM,such as multiparameter flow cytometry,polymerase chain reaction (PCR),next-generation sequencing and positron emission tomography/computed tomography.This review presents an overview of the clinical significance of MRD in patients with MM and charactemitics of four detection techniques for MRD.